These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 23740105)

  • 1. 18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model.
    Chitneni SK; Bida GT; Yuan H; Palmer GM; Hay MP; Melcher T; Wilson WR; Zalutsky MR; Dewhirst MW
    J Nucl Med; 2013 Aug; 54(8):1339-46. PubMed ID: 23740105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models.
    Chitneni SK; Bida GT; Zalutsky MR; Dewhirst MW
    J Nucl Med; 2014 Jul; 55(7):1192-7. PubMed ID: 24854792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5.
    Ziemer LS; Evans SM; Kachur AV; Shuman AL; Cardi CA; Jenkins WT; Karp JS; Alavi A; Dolbier WR; Koch CJ
    Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):259-66. PubMed ID: 12552344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia.
    Wang J; Foehrenbacher A; Su J; Patel R; Hay MP; Hicks KO; Wilson WR
    Clin Cancer Res; 2012 Mar; 18(6):1684-95. PubMed ID: 22167409
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Qian Y; Von Eyben R; Liu Y; Chin FT; Miao Z; Apte S; Carter JN; Binkley MS; Pollom EL; Harris JP; Prionas ND; Kissel M; Simmons A; Diehn M; Shultz DB; Brown JM; Maxim PG; Koong AC; Graves EE; Loo BW
    Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1183-1192. PubMed ID: 29859786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-EF5 PET Is Predictive of Response to Fractionated Radiotherapy in Preclinical Tumor Models.
    Ali R; Apte S; Vilalta M; Subbarayan M; Miao Z; Chin FT; Graves EE
    PLoS One; 2015; 10(10):e0139425. PubMed ID: 26431331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer.
    Komar G; Seppänen M; Eskola O; Lindholm P; Grönroos TJ; Forsback S; Sipilä H; Evans SM; Solin O; Minn H
    J Nucl Med; 2008 Dec; 49(12):1944-51. PubMed ID: 18997048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5.
    Wang J; Guise CP; Dachs GU; Phung Y; Hsu AH; Lambie NK; Patterson AV; Wilson WR
    Biochem Pharmacol; 2014 Oct; 91(4):436-46. PubMed ID: 25130546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A simplified synthesis of the hypoxia imaging agent 2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-[(18)F]pentafluoropropyl)-acetamide ([18F]EF5).
    Chitneni SK; Bida GT; Dewhirst MW; Zalutsky MR
    Nucl Med Biol; 2012 Oct; 39(7):1012-8. PubMed ID: 22727821
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    De Bruycker S; Vangestel C; Van den Wyngaert T; Pauwels P; Wyffels L; Staelens S; Stroobants S
    J Nucl Med; 2019 Jan; 60(1):34-40. PubMed ID: 29980581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging of Tumor Hypoxia With 18F-EF5 PET/MRI in Cervical Cancer.
    Narva SI; Seppänen MP; Raiko JRH; Forsback SJ; Orte KJ; Virtanen JM; Hynninen J; Hietanen S
    Clin Nucl Med; 2021 Dec; 46(12):952-957. PubMed ID: 34619699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schedule-dependent potentiation of chemotherapy drugs by the hypoxia-activated prodrug SN30000.
    Mao X; McManaway S; Jaiswal JK; Hong CR; Wilson WR; Hicks KO
    Cancer Biol Ther; 2019; 20(9):1258-1269. PubMed ID: 31131698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Photodegradation of the benzotriazine 1,4-Di-N-oxide hypoxia-activated prodrug SN30000 in aqueous solution.
    Gu Y; Jaiswal JK; Wang J; Hicks KO; Hay MP; Wilson WR
    J Pharm Sci; 2014 Nov; 103(11):3464-3472. PubMed ID: 25212501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [18F]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure.
    Dolbier WR; Li AR; Koch CJ; Shiue CY; Kachur AV
    Appl Radiat Isot; 2001 Jan; 54(1):73-80. PubMed ID: 11144255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeatability of tumour hypoxia imaging using [
    Silvoniemi A; Suilamo S; Laitinen T; Forsback S; Löyttyniemi E; Vaittinen S; Saunavaara V; Solin O; Grönroos TJ; Minn H
    Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):161-169. PubMed ID: 29075831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of hypoxia by [18F]EF5 in atherosclerotic plaques in mice.
    Silvola JM; Saraste A; Forsback S; Laine VJ; Saukko P; Heinonen SE; Ylä-Herttuala S; Roivainen A; Knuuti J
    Arterioscler Thromb Vasc Biol; 2011 May; 31(5):1011-5. PubMed ID: 21372297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of tumour blood flow, [¹⁸F]EF5 and [¹⁸F]FDG PET/CT imaging in patients with head and neck cancer treated with radiochemotherapy.
    Komar G; Lehtiö K; Seppänen M; Eskola O; Levola H; Lindholm P; Sipilä H; Seppälä J; Grénman R; Solin O; Minn H
    Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2042-50. PubMed ID: 24898846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma.
    Koch CJ; Scheuermann JS; Divgi C; Judy KD; Kachur AV; Freifelder R; Reddin JS; Karp J; Stubbs JB; Hahn SM; Driesbaugh J; Smith D; Prendergast S; Evans SM
    Eur J Nucl Med Mol Imaging; 2010 Nov; 37(11):2048-59. PubMed ID: 20585774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tracer level electrophilic synthesis and pharmacokinetics of the hypoxia tracer [(18)F]EF5.
    Eskola O; Grönroos TJ; Forsback S; Tuomela J; Komar G; Bergman J; Härkönen P; Haaparanta M; Minn H; Solin O
    Mol Imaging Biol; 2012 Apr; 14(2):205-12. PubMed ID: 21448777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer.
    Everitt S; Hicks RJ; Ball D; Kron T; Schneider-Kolsky M; Walter T; Binns D; Mac Manus M
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1098-104. PubMed ID: 19386444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.